S&P 500   3,322.70 (-0.21%)
DOW   29,268.61 (-0.27%)
QQQ   223.34 (-0.02%)
AAPL   317.87 (-0.27%)
FB   220.49 (-0.74%)
MSFT   167.66 (+0.34%)
GOOGL   1,475.94 (-0.24%)
AMZN   1,871.26 (+0.35%)
CGC   24.57 (-1.29%)
NVDA   248.41 (-0.35%)
MU   58.45 (+1.37%)
GE   11.70 (-1.02%)
ACB   2.06 (-3.29%)
F   9.11 (-0.55%)
NFLX   337.60 (-0.61%)
BAC   34.36 (-1.01%)
GILD   62.50 (-0.76%)
DIS   143.19 (-0.79%)
S&P 500   3,322.70 (-0.21%)
DOW   29,268.61 (-0.27%)
QQQ   223.34 (-0.02%)
AAPL   317.87 (-0.27%)
FB   220.49 (-0.74%)
MSFT   167.66 (+0.34%)
GOOGL   1,475.94 (-0.24%)
AMZN   1,871.26 (+0.35%)
CGC   24.57 (-1.29%)
NVDA   248.41 (-0.35%)
MU   58.45 (+1.37%)
GE   11.70 (-1.02%)
ACB   2.06 (-3.29%)
F   9.11 (-0.55%)
NFLX   337.60 (-0.61%)
BAC   34.36 (-1.01%)
GILD   62.50 (-0.76%)
DIS   143.19 (-0.79%)
S&P 500   3,322.70 (-0.21%)
DOW   29,268.61 (-0.27%)
QQQ   223.34 (-0.02%)
AAPL   317.87 (-0.27%)
FB   220.49 (-0.74%)
MSFT   167.66 (+0.34%)
GOOGL   1,475.94 (-0.24%)
AMZN   1,871.26 (+0.35%)
CGC   24.57 (-1.29%)
NVDA   248.41 (-0.35%)
MU   58.45 (+1.37%)
GE   11.70 (-1.02%)
ACB   2.06 (-3.29%)
F   9.11 (-0.55%)
NFLX   337.60 (-0.61%)
BAC   34.36 (-1.01%)
GILD   62.50 (-0.76%)
DIS   143.19 (-0.79%)
S&P 500   3,322.70 (-0.21%)
DOW   29,268.61 (-0.27%)
QQQ   223.34 (-0.02%)
AAPL   317.87 (-0.27%)
FB   220.49 (-0.74%)
MSFT   167.66 (+0.34%)
GOOGL   1,475.94 (-0.24%)
AMZN   1,871.26 (+0.35%)
CGC   24.57 (-1.29%)
NVDA   248.41 (-0.35%)
MU   58.45 (+1.37%)
GE   11.70 (-1.02%)
ACB   2.06 (-3.29%)
F   9.11 (-0.55%)
NFLX   337.60 (-0.61%)
BAC   34.36 (-1.01%)
GILD   62.50 (-0.76%)
DIS   143.19 (-0.79%)
Log in

NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

$96.70
-0.35 (-0.36 %)
(As of 01/21/2020 11:08 AM ET)
Today's Range
$96.63
Now: $96.70
$98.20
50-Day Range
$96.71
MA: $110.63
$128.97
52-Week Range
$55.11
Now: $96.70
$132.59
Volume12,865 shs
Average Volume758,024 shs
Market Capitalization$3.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.93 million
Book Value$5.86 per share

Profitability

Net Income$-98,420,000.00
Net Margins-2,698.66%

Miscellaneous

Employees63
Market Cap$3.81 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.


Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.25) by $0.13. The biotechnology company earned $0.99 million during the quarter, compared to analyst estimates of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

What price target have analysts set for MRTX?

16 analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their forecasts range from $81.00 to $130.00. On average, they expect Mirati Therapeutics' stock price to reach $107.21 in the next year. This suggests a possible upside of 10.6% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

Has Mirati Therapeutics been receiving favorable news coverage?

News coverage about MRTX stock has been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Mirati Therapeutics.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a drop in short interest in December. As of December 13th, there was short interest totalling 4,410,000 shares, a drop of 9.4% from the November 28th total of 4,870,000 shares. Based on an average trading volume of 676,400 shares, the days-to-cover ratio is currently 6.5 days. Currently, 11.4% of the company's stock are sold short. View Mirati Therapeutics' Current Options Chain.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Amarin (AMRN) and Exelixis (EXEL).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.32%), Tocqueville Asset Management L.P. (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Tocqueville Asset Management L.P. and Nisa Investment Advisors LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $96.97.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $3.82 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is http://www.mirati.com/.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  652
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel